Hospital Clínico Universitario de Valencia


Valencia, Spain

Publications in cooperation with FAU scientists

Mayer, I.A., Prat, A., Egle, D., Blau, S., Alejandro Perez Fidalgo, J., Gnant, M.,... Arteaga, C.L. (2019). A phase II randomized study of neoadjuvant letrozole plus alpelisib for hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (NeO-ORB). Clinical Cancer Research, 25(10), 2975-2987.
Wu, W., Jordan, S., Graf, N., Pena, J.D.O., Curram, J., Allanore, Y.,... Puttini, P.S. (2019). Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort. Annals of the Rheumatic Diseases, 78(5), 648-656.
Elhai, M., Distler, O., Smith, V., Matucci-Cerinic, M., Alegre-Sancho, J.J., Truchetet, M.-E.,... Allanore, Y. (2018). RITUXIMAB IN SYSTEMIC SCLEROSIS : SAFETY AND EFFICACY DATA FROM THE EUSTAR NETWORK. (pp. 122-122).
Elhai, M., Meune, C., Boubaya, M., Avouac, J., Hachulla, E., Balbir-Gurman, A.,... Allanore, Y. (2017). Mapping and predicting mortality from systemic sclerosis. Annals of the Rheumatic Diseases.
Loibl, S., De La Pena, L., Nekljudova, V., Zardavas, D., Michiels, S., Denkert, C.,... Loi, S. (2017). Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE). European journal of cancer, 85, 133-145.
Lopez-Isac, E., Martin, J.-E., Assassi, S., Simeon, C.P., Carreira, P., Ortego-Centeno, N.,... Martin, J. (2016). Brief Report: IRF4 Newly Identified as a Common Susceptibility Locus for Systemic Sclerosis and Rheumatoid Arthritis in a Cross-Disease Meta-Analysis of Genome-Wide Association Studies. Arthritis and Rheumatology, 68(9), 2338-44.
Lopez-Isac, E., Bossini-Castillo, L., Simeon, C.P., Victoria Egurbide, M., Jose Alegre-Sancho, J., Luis Callejas, J.,... Martin, J. (2014). A genome-wide association study follow-up suggests a possible role for PPARG in systemic sclerosis susceptibility. Arthritis Research & Therapy, 16(1), R6.

Last updated on 2019-07-03 at 16:28